Literature DB >> 6131958

Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.

L Lennard, J L Maddocks.   

Abstract

An assay for 6-thioguanine (6-TG) nucleotide, a major metabolite of the cytotoxic drugs azathioprine, 6-mercaptopurine and 6-thioguanine in human red blood cells (RBCs) has been developed. The metabolite was not detected in RBCs when azathioprine or 6-mercaptopurine was incubated with whole blood in-vitro. The assay for intracellular 6-TG nucleotide is specific and requires 8 X 10(8) RBCs (100 microliters packed cells) for which the limit of sensitivity is 30 pmole 6-TG nucleotide. Pre-dose blood samples were obtained, 12 h after the last azathioprine dose, from 10 renal transplant recipients with stable functioning cadaver grafts on a total daily dose of 150 mg azathioprine. The mean 6-TG nucleotide concentration was 171 pmole/8 X 10(8) RBCs (s.d. = 84). The assay is also suitable for use in measuring 6-TG nucleotide in the RBCs of leukaemic children undergoing 6-mercaptopurine treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131958     DOI: 10.1111/j.2042-7158.1983.tb04255.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  25 in total

1.  Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

Authors:  P W Lowry; C L Franklin; A L Weaver; M G Pike; D C Mays; W J Tremaine; J J Lipsky; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Peliosis hepatis induced by 6-thioguanine administration.

Authors:  D Larrey; E Fréneaux; A Berson; G Babany; C Degott; D Valla; D Pessayre; J P Benhamou
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

5.  Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.

Authors:  P Lafolie; O Björk; S Hayder; L Ahström; C Peterson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

7.  Severe megaloblastic anaemia associated with abnormal azathioprine metabolism.

Authors:  L Lennard; M F Murphy; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

8.  Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris.

Authors:  L Lennard; C I Harrington; M Wood; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

9.  The accumulation of mercaptopurine metabolites in age fractionated red blood cells.

Authors:  A Rostami-Hodjegan; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

10.  Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia.

Authors:  C A Rees; L Lennard; J S Lilleyman; J L Maddocks
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.